161 related articles for article (PubMed ID: 36524980)
1. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
Cortes JE; Hochhaus A; Takahashi N; Larson RA; Issa GC; Bombaci F; Ramscar N; Ifrah S; Hughes TP
Future Oncol; 2022 Dec; 18(38):4161-4170. PubMed ID: 36524980
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
[TBL] [Abstract][Full Text] [Related]
3. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
Monestime S; Al Sagheer T; Tadros M
Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
[TBL] [Abstract][Full Text] [Related]
4. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
[TBL] [Abstract][Full Text] [Related]
5. Asciminib as a third line option in chronic myeloid leukemia.
Laganà A; Scalzulli E; Carmosino I; Martelli M; Breccia M
Int J Hematol; 2023 Jan; 117(1):16-23. PubMed ID: 35930119
[TBL] [Abstract][Full Text] [Related]
6. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
Hochhaus A; Wang J; Kim DW; Kim DDH; Mayer J; Goh YT; le Coutre P; Takahashi N; Kim I; Etienne G; Andorsky D; Issa GC; Larson RA; Bombaci F; Kapoor S; McCulloch T; Malek K; Yau L; Ifrah S; Hoch M; Cortes JE; Hughes TP;
N Engl J Med; 2024 May; ():. PubMed ID: 38820078
[TBL] [Abstract][Full Text] [Related]
7. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
Manley PW; Barys L; Cowan-Jacob SW
Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
[TBL] [Abstract][Full Text] [Related]
8. Asciminib for chronic myeloid leukaemia: Next questions.
Shanmuganathan N; Hughes TP
Br J Haematol; 2022 Nov; 199(3):322-331. PubMed ID: 35729850
[TBL] [Abstract][Full Text] [Related]
9. The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.
Tesileanu CMS; Michaleas S; Gonzalo Ruiz R; Mariz S; Fabriek BO; van Hennik PB; Dedorath J; Dekic B; Unkrig C; Brandt A; Koenig J; Enzmann H; Delgado J; Pignatti F
Oncologist; 2023 Jul; 28(7):628-632. PubMed ID: 37141403
[TBL] [Abstract][Full Text] [Related]
10. Asciminib in chronic myeloid leukemia.
Assanto GM; Scalzulli E; Breccia M
Drugs Today (Barc); 2022 Oct; 58(10):479-489. PubMed ID: 36305542
[TBL] [Abstract][Full Text] [Related]
11. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
[TBL] [Abstract][Full Text] [Related]
12. Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.
Combes FP; Li YF; Hoch M; Lorenzo S; Ho YY; Sy SKB
Clin Pharmacol Ther; 2022 Nov; 112(5):1040-1050. PubMed ID: 35776072
[TBL] [Abstract][Full Text] [Related]
13. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
[TBL] [Abstract][Full Text] [Related]
15. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
Mauro MJ; Hughes TP; Kim DW; Rea D; Cortes JE; Hochhaus A; Sasaki K; Breccia M; Talpaz M; Ottmann O; Minami H; Goh YT; DeAngelo DJ; Heinrich MC; Gómez-García de Soria V; le Coutre P; Mahon FX; Janssen JJWM; Deininger M; Shanmuganathan N; Geyer MB; Cacciatore S; Polydoros F; Agrawal N; Hoch M; Lang F
Leukemia; 2023 May; 37(5):1048-1059. PubMed ID: 36949155
[TBL] [Abstract][Full Text] [Related]
16. Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
Padala S; Cortes J
Haematologica; 2023 Nov; 108(11):2913-2918. PubMed ID: 37102603
[TBL] [Abstract][Full Text] [Related]
17. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D; Hughes TP
Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
[TBL] [Abstract][Full Text] [Related]
18. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q; Li Z; Qin Y; Li W; Xu N; Liu B; Zhang Y; Meng L; Zhu H; Du X; Chen S; Liang Y; Hu Y; Liu X; Song Y; Men L; Chen Z; Niu Q; Wang H; Lu M; Yang D; Zhai Y; Huang X
J Hematol Oncol; 2022 Aug; 15(1):113. PubMed ID: 35982483
[TBL] [Abstract][Full Text] [Related]
19. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
García-Gutiérrez V; Hernandez-Boluda JC
Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]